Reed F. Johnson

This study compares intranasal and intramuscular vaccines, finding that the intranasal Ad4-S vaccine provides more durable and effective immune responses against SARS-CoV-2 in preclinical models.

This study evaluates intranasal B/HPIV3 vaccines expressing SARS-CoV-2 spike proteins of different variants, showing they induce mucosal and systemic immunity and protect hamsters against homologous and heterologous challenges.

This study shows that pre-existing lung inflammation reduces SARS-CoV-2 replication by activating innate immune pathways, highlighting the role of the inflammatory microenvironment in controlling viral infection.